Genentech

Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer

Tuesday, December 1, 2020 - 8:15pm

GAVRETO is jointly commercialized in the U.S. by Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, under Blueprint Medicines' collaboration with Roche.

Key Points: 
  • GAVRETO is jointly commercialized in the U.S. by Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, under Blueprint Medicines' collaboration with Roche.
  • Earlier this year, the FDA granted accelerated approval to GAVRETO for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
  • The continued approval of GAVRETO for advanced or metastatic RET-altered thyroid cancers may be contingent upon verification and description of clinical benefit in confirmatory trials.
  • Blueprint Medicines is dedicated to helping patients access GAVRETO and delivering support throughout their treatment journey.

Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology

Tuesday, December 1, 2020 - 12:30pm

Dr. Sandler was most recently the Senior Vice President and Global Head of Product Development Oncology at Genentech, a member of the Roche Group.

Key Points: 
  • Dr. Sandler was most recently the Senior Vice President and Global Head of Product Development Oncology at Genentech, a member of the Roche Group.
  • We are delighted to welcome Alan to Zai Lab as we continue to expand globally and strengthen our R&D leadership, said Dr. Samantha Du, Founder, Chairwoman and CEO of Zai Lab.
  • We look forward to his leadership of our oncology franchise as we advance towards our goal of becoming a leading global biopharma company.
  • Im very excited to be joining Zai Lab, given its robust pipeline of innovative clinical compounds, said Dr. Sandler.

FDA Expands Approval of Influenza Treatment to Post-Exposure Prevention

Monday, November 23, 2020 - 5:41pm

Xofluza, previously available only in tablet form, is also now available as granules for mixing in water.

Key Points: 
  • Xofluza, previously available only in tablet form, is also now available as granules for mixing in water.
  • Flu is a contagious respiratory illness caused by influenza viruses .
  • Treating flu patients with antiviral drugs within 48 hours of their becoming sick can reduce symptoms and duration of the illness.
  • The FDA granted the approval of Xofluza to Genentech USA, Inc.

Howard University Student Pharmacist Presents Critical Research Following the Conclusion of AMCP Foundation and Genentech Internship

Friday, November 20, 2020 - 11:57pm

Now in its seventh year, the AMCP Foundation and Genentech, a member of the Roche Group.

Key Points: 
  • Now in its seventh year, the AMCP Foundation and Genentech, a member of the Roche Group.
  • "Career journeys in managed care launch each summer through AMCP Foundation internships," said Executive Director Paula J. Eichenbrenner, MBA, CAE.
  • AMCP Foundation congratulates Mr. Taylor for completing the 2020 Evidence for Access Summer Internship Program in partnership with Genentech.
  • Established in 1990, the 501(c)3 nonprofit AMCP Foundation is the philanthropic arm of the Academy of Managed Care Pharmacy (AMCP).

GO2 Foundation for Lung Cancer Recognizes the Lung Cancer Community at Simply the Best XV Virtual Gala

Sunday, November 15, 2020 - 1:30am

SAN CARLOS, Calif. and WASHINGTON, Nov. 14, 2020 /PRNewswire/ --GO2 Foundation for Lung Cancer (GO2 Foundation) will honor leaders in lung cancer research and treatment, as well as dedicated lung cancer caregivers, at its Simply the Best XV Virtual Gala tonight.

Key Points: 
  • SAN CARLOS, Calif. and WASHINGTON, Nov. 14, 2020 /PRNewswire/ --GO2 Foundation for Lung Cancer (GO2 Foundation) will honor leaders in lung cancer research and treatment, as well as dedicated lung cancer caregivers, at its Simply the Best XV Virtual Gala tonight.
  • Even in the midst of a pandemic, those working in the lung cancer community have still accomplished much and have not skipped a beat," said Bonnie J. Addario, GO2 Foundation founder and chair.
  • The Dr. Fred Marcus Simply the Best Award: Genentech
    Genentech will receive this award for outstanding performance in the fight to end lung cancer.
  • Genentech has been committed to developing innovative treatments for people with serious and life-threatening medical conditions like lung cancer for 40 years and has been a GO2 Foundation partner since its inception in 1995.

Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress

Tuesday, November 10, 2020 - 11:30am

Revenue for the third quarter of 2020 and 2019 predominantly relate to the Genentech collaboration (2020: 10.5 million, 2019: 1.9 million).

Key Points: 
  • Revenue for the third quarter of 2020 and 2019 predominantly relate to the Genentech collaboration (2020: 10.5 million, 2019: 1.9 million).
  • G&A expenses for the third quarter of 2020 were 3.5 million compared to 2.8 million in the third quarter of 2019.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.
  • Affimed will host a conference call and webcast today, Tuesday, November 10, 2020 at 8:30 a.m. EST to discuss third quarter 2020 financial results and recent corporate developments.

China Rituximab Market Investigation Report 2020: Market Share of Roche and Genentech will Continue to Decline in 2020-2024

Monday, November 9, 2020 - 6:00pm

DUBLIN, Nov. 9, 2020 /PRNewswire/ -- The "Investigation Report on China's Rituximab Market, 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 9, 2020 /PRNewswire/ -- The "Investigation Report on China's Rituximab Market, 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • According to this market research, in 2019, the sales value of Rituximab reached CNY1.42 billion(US$206 million) in China.
  • According to the market research, it is expected that with the launch of more domestic rituximab products in China, the market share of Roche and Genentech will continue to decline in 2020-2024.
  • But for a long period of time, Roche and Genentech will still occupy the major market share of rituximab in China.

The Glioblastoma Multiforme Market is set to soar high with a CAGR of 8.25% in the 7MM for the Study Period 2017-30, estimates DelveInsight

Monday, November 9, 2020 - 2:30pm

DelveInsight's Glioblastoma Multiforme Market report delivers an in-depth understanding of the Glioblastoma multiforme, historical and forecasted epidemiology trends as well as the Glioblastoma multiforme market landscape, and forecast in the 7MM (the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan) for the study period of 2017-2030.

Key Points: 
  • DelveInsight's Glioblastoma Multiforme Market report delivers an in-depth understanding of the Glioblastoma multiforme, historical and forecasted epidemiology trends as well as the Glioblastoma multiforme market landscape, and forecast in the 7MM (the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan) for the study period of 2017-2030.
  • Glioblastoma multiforme market report highlights:
    The present Glioblastoma multiforme treatment market offers Avastin (Genentech) as the first clinically available angiogenesis inhibitor in the United States.
  • However, several companies are working in the Glioblastoma multiforme market landscape to address the prevailing unmet needs in the treatment market.
  • The Glioblastoma multiforme pipeline constitutes novel and diverse therapeutic agents to be launched in the coming decade.

The Glioblastoma Multiforme Market is set to soar high with a CAGR of 8.25% in the 7MM for the Study Period 2017-30, estimates DelveInsight

Monday, November 9, 2020 - 2:30pm

DelveInsight's Glioblastoma Multiforme Market report delivers an in-depth understanding of the Glioblastoma multiforme, historical and forecasted epidemiology trends as well as the Glioblastoma multiforme market landscape, and forecast in the 7MM (the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan) for the study period of 2017-2030.

Key Points: 
  • DelveInsight's Glioblastoma Multiforme Market report delivers an in-depth understanding of the Glioblastoma multiforme, historical and forecasted epidemiology trends as well as the Glioblastoma multiforme market landscape, and forecast in the 7MM (the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan) for the study period of 2017-2030.
  • Glioblastoma multiforme market report highlights:
    The present Glioblastoma multiforme treatment market offers Avastin (Genentech) as the first clinically available angiogenesis inhibitor in the United States.
  • However, several companies are working in the Glioblastoma multiforme market landscape to address the prevailing unmet needs in the treatment market.
  • The Glioblastoma multiforme pipeline constitutes novel and diverse therapeutic agents to be launched in the coming decade.

Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition

Wednesday, November 4, 2020 - 6:29pm

"In addition to the data published in the abstracts this morning, we look forward to providing updated safety and efficacy data at ASH from both studies."

Key Points: 
  • "In addition to the data published in the abstracts this morning, we look forward to providing updated safety and efficacy data at ASH from both studies."
  • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma Clinical Studies: Poster III
    Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer.
  • In 2015, Curis entered into a collaborationwith Aurigene in the areas of immuno-oncology and precision oncology.
  • Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge for the treatment of advanced basal cell carcinoma.